CompletedNCT00890240
Single-dose JNJ-31001074 in children aged 6–11 with ADHD
About this title
A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)
Read the official source — NCT00890240This study evaluated the safety of JNJ-31001074 for people with ADHD.
Medication studyAges 6–11
Understand this study
What did researchers investigate?
This study evaluated the safety of JNJ-31001074 for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateMay 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 18
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Not clearly listed
- Age range
- From 6 Years to 11 Years
- Official registry ID
- NCT00890240
- Official title
Show the full official title
An Open-Label, Multi-Center, Sequential Group, Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of JNJ-31001074 After a Single Dose Administration in Pediatric Subjects With Attention-Deficit/Hyperactivity Disorder, 6 to 11 Years Old
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
This study evaluated the safety of JNJ-31001074 for people with ADHD.
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including JNJ-31001074.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD